Toxicology — Organophosphate Poisoning

Organophosphate poisoning represents acute cholinergic toxicity resulting from inhibition of acetylcholinesterase (AChE), the enzyme responsible for degrading acetylcholine at synaptic and neuromuscular junctions. These compounds—including pesticides (parathion, malathion), nerve agents (sarin, VX), and some pharmaceutical agents—pose significant public health threats in both occupational and intentional exposure contexts. Organophosphate poisoning accounts for approximately 3 million exposures annually worldwide with mortality rates of 3-25% depending on agent and exposure route, and remains a leading cause of pesticide-related deaths in developing nations. For medical students and residents, recognition of the cholinergic crisis and rapid antidotal therapy are essential competencies, as minutes matter in determining survival and neurological outcomes. The condition tests fundamental understanding of autonomic physiology, toxicology principles, and emergency medicine management.

Organophosphate compounds produce toxicity through irreversible inhibition of acetylcholinesterase, leading to accumulation of acetylcholine and unopposed cholinergic stimulation across muscarinic, nicotinic, and central nervous system receptors.

Organophosphates phosphorylate the serine residue (Ser203 in human butyrylcholinesterase) at the active site of acetylcholinesterase, preventing the enzyme's normal catalytic hydrolysis of acetylcholine. Unlike carbamate compounds that form reversible carbamyl-enzyme complexes, organophosphate-enzyme bonds are covalent and highly stable. Critical to clinical management is the process of "aging," wherein the phosphorylated enzyme undergoes dealkylation over hours to days, creating an even more stable complex that cannot be reversed by standard antidotes like pralidoxime (2-PAM). Once aging occurs (timing varies by agent: minutes for some nerve agents, hours for many pesticides), the enzyme-inhibitor complex becomes essentially permanent, requiring de novo AChE synthesis for functional recovery. This explains why early administration of pralidoxime before aging becomes complete is crucial for therapeutic efficacy.

As acetylcholinesterase becomes progressively inhibited, acetylcholine accumulates in synaptic and neuromuscular clefts, producing sustained, unopposed stimulation of muscarinic (M1-M5), nicotinic (skeletal muscle, neuronal), and central cholinergic receptors. At muscarinic receptors in parasympathetic-innervated organs (heart, bronchi, GI tract, bladder), excessive acetylcholine causes enhanced parasympathetic tone manifesting as miosis, bronchospasm, bradycardia, hypersalivation, and lacrimation. At nicotinic receptors on skeletal muscle, acetylcholine first causes initial depolarization and fasciculations (visible muscle twitching), followed by depolarization blockade and flaccid paralysis as sustained depolarization prevents re-polarization and muscle action potential generation. Nicotinic effects at sympathetic ganglia contribute to sympathomimetic signs (tachycardia, hypertension) that may initially overshadow parasympathetic signs. Central nervous system accumulation of acetylcholine produces seizures, altered consciousness, and respiratory center depression.

Death in organophosphate poisoning results primarily from respiratory failure via multiple mechanisms: (1) direct bronchospasm and excessive bronchial secretions leading to airway obstruction, (2) paralysis of respiratory muscles due to nicotinic blockade at the neuromuscular junction, and (3) central respiratory depression from CNS cholinergic excess. The combination of blocked airways (due to bronchospasm and secretions) and weakened respiratory muscles creates a mechanically impossible situation without mechanical ventilation. Additionally, the "intermediate syndrome" may develop 24-96 hours post-exposure in severe cases, characterized by loss of nicotinic symptoms and emergence of muscle weakness that can precipitate sudden respiratory decompensation even after initial apparent improvement.

Agricultural workers, pesticide applicators, and manufacturing plant employees constitute the highest-risk population for organophosphate exposure. Inadequate personal protective equipment (PPE), improper mixing or application techniques, and work in poorly regulated environments significantly increase risk. Exposure routes include dermal (most common), inhalation, ingestion, and transdermal penetration through skin or clothing. Tropical and subtropical regions with high pesticide use and limited occupational safety standards report the highest incidence of accidental occupational poisoning.

In developing nations, particularly rural India and South Asia, organophosphate pesticides represent one of the most common methods of suicide, accounting for 20-30% of all pesticide-related deaths. Easy accessibility of agricultural-grade pesticides combined with impulsive access during emotional crises creates a unique epidemiologic pattern in these regions. Homicidal poisoning via contaminated food or beverage is less common but well-documented in forensic toxicology literature.

Accidental ingestion can occur from contamination of stored foodstuffs with pesticide containers, particularly in households with poor storage practices. Children may be exposed through dermal contact with recently sprayed vegetation or contaminated clothing worn by agricultural workers. Intentional poisoning of agricultural competitors or livestock has been documented in agricultural disputes.

Echothiophate (used as ophthalmic drops for glaucoma and accommodation disorders, though largely superseded) and disulfiram (at high doses) can produce organophosphate-like toxicity through acetylcholinesterase inhibition, albeit through different mechanisms than true organophosphates.

Chemical warfare agents including sarin, VX, tabun, and soman are organophosphates weaponized for mass casualty events. The Tokyo subway sarin attack (1995) and Syria's documented sarin use remain modern examples relevant to emergency preparedness.

The clinical manifestations of organophosphate poisoning follow a predictable pattern reflecting progressive cholinergic excess, though the speed of symptom onset varies from minutes (inhalation/ingestion) to hours (dermal exposure).

Miosis results from sustained muscarinic stimulation of the pupillary sphincter muscle (parasympathetic-innervated), producing characteristic pinpoint pupils (often described as "pinpoint pupils like a heroin addict," though the context differs). Miosis typically appears within minutes of significant exposure and persists longer than other muscarinic signs, making it an important diagnostic clue in the post-resuscitation phase when other acute signs may have been treated. In severe poisoning, pupils may be so constricted that they appear as barely visible slits. Importantly, miosis may be absent in mild poisoning or with certain highly lipophilic agents that preferentially affect nicotinic sites.

Muscarinic stimulation of salivary, lacrimal, and bronchial mucous glands produces copious secretions that are often the most striking clinical sign at presentation. Patients present with "pulmonary flooding," described clinically as resembling pulmonary edema but actually representing cholinergic bronchorrhea and bronchoconstriction. The phrase "pulmonary edema in a pink patient" is classic—pulmonary fluid is clear rather than pink-tinged as in cardiogenic edema, and the patient's pink complexion reflects adequate oxygenation despite respiratory distress. This distinguishes it from true pulmonary edema and guides fluid management (avoid additional fluids that would worsen secretions).

Direct smooth muscle contraction in bronchi and bronchioles occurs through muscarinic M3 receptor stimulation, producing wheezing, stridor, and respiratory distress even without parenchymal involvement. Combined with excessive secretions and depressed respiratory drive, bronchospasm creates a triple threat to oxygenation and ventilation.

Enhanced parasympathetic tone produces diarrhea (often profuse and watery), nausea, vomiting, and abdominal cramping due to increased GI motility and secretion. The mnemonic SLUDGE (Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis) captures the acute cholinergic syndrome, though this mnemonic is more complete when modified to include nicotinic and CNS signs.

In moderate to severe poisoning, visible fasciculations (fine, rapid muscle twitching visible under the skin) occur within seconds to minutes, reflecting uncontrolled nicotinic receptor depolarization. These fasciculations are pathognomonic and provide crucial diagnostic information. As poisoning progresses, depolarization blockade ensues, producing flaccid paralysis of skeletal muscles including respiratory muscles (diaphragm, intercostals). Patients may retain consciousness despite complete paralysis—a terrifying experience that underscores the importance of reassurance and sedation during intubation. Masseter muscle rigidity may impede mouth opening during intubation attempts.

Muscarinic M2 receptor stimulation at the sinoatrial node produces bradycardia, sometimes profound (heart rates in the 30s-40s). Atrial fibrillation and atrioventricular block can occur. Paradoxically, some patients (particularly with less lipophilic agents or milder exposures) may initially present with tachycardia and hypertension due to predominant nicotinic ganglionic stimulation—a finding that can create diagnostic confusion.

Central nervous system acetylcholine accumulation produces anxiety, tremor, confusion, altered consciousness ranging to coma, and generalized seizures. Seizures may be refractory to standard anticonvulsants if cholinergic excess is not concurrently treated. Status epilepticus constitutes a medical emergency with high mortality.

Muscarinic stimulation of bladder detrusor muscle produces urinary frequency and incontinence, often overlooked clinically but part of the complete cholinergic picture.

Mild Poisoning: Limited to miosis, salivation, and mild respiratory symptoms, manageable with atropine and observation.

Moderate Poisoning: Includes obvious bronchospasm, bradycardia, and mild paralysis; requires aggressive antidotal therapy and possible intubation.

Severe/Fulminant Poisoning: Presents with rapid progression to apnea, profound bradycardia or dysrhythmia, seizures, and complete paralysis; mortality without ICU management approaches 100%.

Intermediate Syndrome: Emerges 24-96 hours after exposure (typically with certain organophosphates like fenthion, dimethoate) as acute cholinergic signs resolve but nicotinic weakness paradoxically worsens, producing respiratory muscle weakness and cranial nerve palsies. This represents a distinct phase that can cause sudden death if not anticipated and supported mechanically.

Diagnosis of organophosphate poisoning is primarily clinical and epidemiologic rather than dependent on laboratory confirmation, which is crucial since treatment cannot be delayed pending test results.

The diagnosis should be strongly suspected in any patient presenting with the triad of: (1) miosis, (2) excessive secretions (salivation, bronchorrhea), and (3) fasciculations/paralysis in the context of appropriate exposure history. Even without explicit exposure history, this triad in an acute presentation warrants empiric antidotal therapy. A detailed exposure history (agricultural/pesticide contact, recent spraying in vicinity, intentional ingestion, timeline of symptom onset) provides critical context. Witnesses may report exposure to "pesticide smell" or the patient may have chemical stains on clothing.

This is the most specific laboratory test for organophosphate poisoning, measuring the actual enzyme activity of acetylcholinesterase in red blood cells.

RBC-AChE is highly specific for organophosphate or carbamate poisoning but has limitations: (1) requires 30-60 minutes for results, (2) baseline values vary between individuals requiring paired samples for confirmation, (3) results available only at specialized laboratories, not point-of-care. Therefore, RBC-AChE is not useful for acute triage decisions but confirms the diagnosis retrospectively and helps differentiate organophosphate/carbamate poisoning from other causes of acute cholinergic symptoms.

Plasma cholinesterase, synthesized in the liver, is more rapidly depleted than RBC-AChE and returns to normal faster.

Plasma cholinesterase is less specific than RBC-AChE (genetic variants in the population, liver disease, pregnancy, and medications affect levels) and more variable, but can provide supporting evidence. The ratio of RBC-AChE to plasma cholinesterase may help differentiate organophosphate (both depleted) from carbamate (primarily plasma depleted) poisoning.

The ECG may show sinus bradycardia, prolonged PR or QT intervals, AV block, or atrial fibrillation. These findings are supportive but non-specific and are present concurrently with clinical signs rather than aiding diagnosis.

ABG may reveal hypoxemia and hypercapnia reflecting respiratory insufficiency from bronchospasm, secretions, and muscle weakness. Early in presentation, patients may maintain adequate oxygenation if ventilation is supported and secretions cleared. As respiratory failure develops, progressive hypercapnia becomes apparent, indicating need for mechanical ventilation.

Several conditions can mimic organophosphate poisoning: